| abstract |
FIELD: organic chemistry, medicine, pharmacy. n SUBSTANCE: invention relates to derivatives of 1-arenesulfonyl-2-arylpyrrolidine and piperidine of the formula (I): n wherein R 1 means hydrogen atom (H), (C 1 -C 7 )-alkyl; R 2 means furyl, thienyl, pyridyl or phenyl optionally substituted with 1-3 substitutes taken among (C 1 -C 7 )-alkyl, (C 1 -C 7 )-alkoxy-group, halogen atom, cyano-group, CF 3 or -N(R 4 ) 2 ; R 3 means naphthyl or phenyl optionally substituted with 1-3 substitutes taken among (C 1 -C 7 )-alkyl, (C 1 -C 7 )-alkoxy-group, halogen atom, acetyl, cyano-group, hydroxy-(C 1 -C 7 )-alkyl, -CH 2 -morpholine-4-yl, (C 1 -C 7 )-alkyloxy-(C 1 -C 7 )-alkyl, (C 1 -C 7 )-alkyl-N(R 4 ) 2 or CF 3 ; R 4 means independently of one another hydrogen atom (H), (C 1 -C 7 )-alkyl with exception for (RS)-2-phenyl-1-(toluene-4-sulfonyl)pyrrolidine, (RS)-1-(toluene-4-sulfonyl)-2-p-tolylpyrrolidine, N-tosyl-cis-3-methyl-2-phenylpyrrolidine, 3-[1-(toluene-4-sulfonyl)pyrrolidine-2-yl]pyridine and N-tosyl-2-(3,4-dimethoxyphenyl)pyrrolidine, and their pharmaceutically acceptable salts also. Compounds of the formula (I) elicit the effect of agonists or antagonists of metabotropic glutamate receptors that allows their using in pharmaceutical agent useful for treatment or prophylaxis of acute and/or chronic neurological disturbances. n EFFECT: valuable medicinal properties of compounds. n 9 cl, 1 tbl, 3 sch, 94 ex |